Keyword: OxyContin

Even as the U.S. opioid crisis deepened and lawsuits flourished, Purdue Pharma continued to market Oxycontin to doctors. But no longer.

New Hampshire filed a lawsuit against Purdue Pharma for allegedly leading an information campaign to boost opioid perception among prescribers.

Purdue, which has been fending off lawsuits over pain drug OxyContin in the U.S., may have to face off against Canada’s federal government.

Ohio’s attorney general is going after drugmakers for alleged “fraudulent marketing practices” on opioid painkillers.

Embroiled in a web of allegations and investigations over Subsys marketing, Insys Therapeutics faces a new lawsuit.

OxyContin-makers Purdue and Mundipharma are taking their sales push global.

With employers bearing a big chunk of the cost of opioid abuse,  at least some companies are addressing the issue head-on with efforts to direct employees away from painkiller prescriptions.  

New accusations are raining down on Oxycontin maker Purdue Pharma, and a U.S. senator has called on the FDA, the FTC and the DOJ all to investigate. The latest claim? That Purdue downplayed evidence the painkiller wore off much faster than its labeled 12 hours in many people, making them more likely to get addicted.